Response to Treatment 4 weeks [clinicaltrials_resource:f43dfb327b61825ceff026ba1e62dca8]
To estimate the proportion of patients with steroid refractory acute Graft vs Host Disease) GvHD who respond (PR + CR) to Alpha-1 Antitrypsin (AAT) at a dose of 60mg/kg twice weekly for 8 doses
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Response to Treatment 4 weeks [clinicaltrials_resource:f43dfb327b61825ceff026ba1e62dca8]
To estimate the proportion of patients with steroid refractory acute Graft vs Host Disease) GvHD who respond (PR + CR) to Alpha-1 Antitrypsin (AAT) at a dose of 60mg/kg twice weekly for 8 doses
Bio2RDF identifier
f43dfb327b61825ceff026ba1e62dca8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f43dfb327b61825ceff026ba1e62dca8
measure [clinicaltrials_vocabulary:measure]
Response to Treatment
time frame [clinicaltrials_vocabulary:time-frame]
description
To estimate the proportion of ...... mg/kg twice weekly for 8 doses
identifier
clinicaltrials_resource:f43dfb327b61825ceff026ba1e62dca8
title
Response to Treatment 4 weeks
@en
type
label
Response to Treatment 4 weeks [clinicaltrials_resource:f43dfb327b61825ceff026ba1e62dca8]
@en